3295 Participants Needed

Lenacapavir for HIV Prevention

(PURPOSE 2 Trial)

Recruiting at 102 trial locations
GC
Overseen ByGilead Clinical Study Information Center
Age: Any Age
Sex: Any
Trial Phase: Phase 3
Sponsor: Gilead Sciences
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise
Approved in 1 JurisdictionThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing lenacapavir, a drug that may help prevent HIV. It targets people who are at risk of getting HIV. The drug works by stopping the virus from making more copies of itself. Lenacapavir was developed by Gilead Sciences Inc. and has been approved for use in combination with other treatments.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is lenacapavir safe for humans?

Lenacapavir has been generally well tolerated in clinical trials, with common mild to moderate side effects like injection site reactions, stomach issues, and headaches. It has been studied for treating multidrug-resistant HIV, and ongoing studies are evaluating its use for HIV prevention.12345

What makes the drug Lenacapavir unique for HIV prevention?

Lenacapavir is unique because it is a long-acting injectable drug that targets the HIV-1 capsid (a protein shell of the virus), allowing for dosing every six months, which reduces the need for daily pills. This makes it different from most current HIV treatments that require daily administration.12346

What data supports the effectiveness of the drug Lenacapavir for HIV prevention?

Lenacapavir has shown effectiveness in treating multidrug-resistant HIV, as it is a long-acting drug that can be used in combination with other treatments. It has been approved for use in people with limited treatment options, demonstrating its potential in managing HIV.12378

Who Is on the Research Team?

GS

Gilead Study Director

Principal Investigator

Gilead Sciences

Are You a Good Fit for This Trial?

This trial is for individuals at risk of HIV infection who have had condomless receptive anal sex with male partners, used stimulants during sex recently, or had certain sexually transmitted infections. They must have a kidney function test result (eGFR) ≥ 60 mL/min and not previously taken long-acting PrEP or oral PrEP in the past 12 weeks.

Inclusion Criteria

I've had unprotected receptive anal sex with 2 or more partners in the last 3 months.
Negative local rapid fourth generation HIV-1/2 Ab/Ag, central fourth generation HIV-1/2 Ab/Ag, and HIV-1 RNA quantitative nucleic acid amplification testing (NAAT)
My kidney function, measured by eGFR, is 60 mL/min or higher.
See 15 more

Exclusion Criteria

Randomized Phase:
I have acute or chronic hepatitis A, B, or C.
I have received an HIV vaccine or broadly neutralizing antibody.
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Blinded Phase

Participants receive either SC lenacapavir or placebo every 26 weeks, with oral F/TDF or PTM LEN for approximately 52 weeks

52 weeks
Visits every 26 weeks

PK Tail Phase

Participants who discontinue early or choose not to continue in the LEN OLE Phase receive oral F/TDF or F/TAF for 78 weeks

78 weeks
Visits every 13 weeks

LEN Open-Label Extension (OLE) Phase

Participants continue or switch to SC LEN 927 mg every 26 weeks, with visits every 13 weeks, until LEN is available or study is discontinued

Variable
Visits every 13 weeks

Follow-up

Participants transition to local PrEP services and have a 30-day follow-up visit after study completion or early exit

30 days
1 visit

What Are the Treatments Tested in This Trial?

Interventions

  • F/TAF
  • F/TDF
  • Lenacapavir
Trial Overview The study tests Lenacapavir's effectiveness in preventing HIV. Participants will receive either oral Lenacapavir, subcutaneous Lenacapavir, placebos, or other pre-exposure prophylaxis drugs like F/TDF (and F/TAF for US participants).
How Is the Trial Designed?
4Treatment groups
Experimental Treatment
Group I: PK Tail PhaseExperimental Treatment2 Interventions
Group II: LEN Open-Label Extension (OLE) PhaseExperimental Treatment2 Interventions
Group III: Blinded Phase: Placebo LEN + F/TDFExperimental Treatment3 Interventions
Group IV: Blinded Phase: LEN + Placebo-to-match (PTM) F/TDFExperimental Treatment3 Interventions

Lenacapavir is already approved in United States for the following indications:

🇺🇸
Approved in United States as Sunlenca for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Gilead Sciences

Lead Sponsor

Trials
1,150
Recruited
878,000+
Daniel O'Day profile image

Daniel O'Day

Gilead Sciences

Chief Executive Officer since 2019

MBA from Columbia University

Dietmar Berger profile image

Dietmar Berger

Gilead Sciences

Chief Medical Officer

MD and PhD from Albert-Ludwigs University School of Medicine

Published Research Related to This Trial

Lenacapavir (LEN) is a novel capsid inhibitor that offers a unique treatment option for heavily treatment-experienced (HTE) HIV-1 patients, demonstrating efficacy in achieving viral suppression and immune restoration when combined with other antiretrovirals.
Administered subcutaneously twice a year, lenacapavir provides a convenient dosing schedule, making it a well-tolerated and effective addition to existing HIV treatment regimens.
Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV.Tailor, MW., Chahine, EB., Koren, D., et al.[2023]
Lenacapavir is the first FDA-approved capsid inhibitor for treating multidrug-resistant HIV-1, specifically for heavily treatment-experienced adults whose current therapies are failing due to resistance or safety issues.
In a phase 3 clinical trial, lenacapavir significantly reduced viral load compared to placebo, and it is administered as a long-acting injection every 6 months, although 63% of participants experienced injection site reactions.
Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV.Prather, C., Lee, A., Yen, C.[2023]
Lenacapavir (LEN) is effective against HIV-1, showing no cross-resistance with entry inhibitors in a study of 72 participants, making it a viable treatment option for heavily treatment-experienced individuals with multidrug resistance.
In the CAPELLA study, only 13% of participants developed resistance mutations to LEN after 52 weeks, indicating that LEN maintains its efficacy even in patients with a history of treatment failure.
Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA.Margot, N., Pennetzdorfer, N., Naik, V., et al.[2023]

Citations

Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV. [2023]
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial. [2023]
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. [2023]
Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV. [2023]
Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options. [2023]
Lenacapavir: A novel injectable HIV-1 capsid inhibitor. [2023]
Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA. [2023]
Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security